develop
novel
drug
complex
riski
expens
timeconsum
ventur
estim
convent
drug
discoveri
process
end
new
medicin
readi
market
take
year
billion
usd
fortun
scenario
recent
chang
arriv
new
approach
mani
novel
technolog
methodolog
develop
increas
effici
drug
discoveri
process
comput
methodolog
becom
crucial
compon
mani
drug
discoveri
program
hit
identif
lead
optim
techniqu
ligandor
structurebas
virtual
screen
wide
use
mani
discoveri
effort
case
design
potenti
anticanc
drug
drug
candid
comput
approach
major
impact
year
provid
fruit
insight
field
cancer
paper
review
concept
ration
design
present
repres
exampl
molecul
identifi
mean
key
principl
illustr
case
studi
includ
specif
success
achiev
field
anticanc
drug
design
demonstr
research
advanc
aid
silico
drug
design
potenti
creat
novel
anticanc
drug
descubrimiento
de
asistido
por
ordenador
de
computacional
para
el
descubrimiento
de
contra
el
resumen
el
desarrollo
de
un
nuevo
es
un
proceso
complejo
arriesgado
que
requier
una
enorm
cantidad
de
tiempo
dinero
se
estima
que
el
proceso
para
producir
un
nuevo
desd
su
descubrimiento
hasta
que
acaba
en
el
mercado
pued
tardar
hasta
de
blanco
de
hit
de
tener
un
costo
de
mil
millon
de
usd
por
fortuna
est
escenario
ha
cambiado
recientement
con
la
llegada
de
nueva
entr
ella
lo
computacional
se
han
convertido
en
un
component
determinant
en
mucho
programa
de
descubrimiento
de
en
un
esfuerzo
por
incrementar
la
posibilidad
de
encontrar
nueva
con
potenci
se
utilizan
como
el
cribado
virtual
de
quimioteca
construida
con
base
en
ligando
estructura
para
la
de
hit
hasta
para
la
de
compuesto
en
lo
que
respecta
al
descubrimiento
de
nuevo
candidato
contra
el
esto
enfoqu
tienen
la
fecha
un
impacto
important
aportan
nueva
posibilidad
en
est
se
revisa
el
concepto
del
racion
de
con
potenci
ilustrando
lo
principio
clave
con
alguno
de
lo
ejemplo
representativo
exitoso
de
identificada
mediant
esta
aproximacion
se
incluyen
caso
desarrollado
en
el
campo
del
de
contra
el
con
la
finalidad
de
mostrar
con
la
ayuda
del
asistido
por
computadora
se
pueden
generar
nuevo
que
den
esperanza
millon
de
pacient
nobel
prize
physiolog
medicin
award
jointli
ernst
bori
chain
sir
howard
walter
florey
sir
alexand
fleme
mass
product
penicillin
discov
latter
almost
two
decad
time
averag
life
expect
birth
mexico
year
current
life
expect
newborn
around
year
increas
explain
mani
factor
includ
signific
amount
medic
physician
prescrib
today
extend
life
patient
effect
medicin
base
interact
therapeut
chemic
compound
drug
protein
target
gproteincoupl
receptor
ion
channel
proteas
kinas
nuclear
hormon
receptor
among
other
therefor
might
wonder
mani
new
drug
still
discov
research
answer
would
almost
unlimit
quantiti
number
potenti
target
remain
unclear
howev
recent
estim
claim
number
current
target
order
magnitud
lower
could
hand
number
organ
molecul
act
drug
also
matter
debat
million
small
chemic
compound
alreadi
synthes
screen
specif
target
public
privat
laboratori
addit
matter
quantiti
also
qualiti
recent
medicin
discov
either
result
unexpect
investig
inspect
natur
substanc
tradit
consid
therapeut
extens
experiment
blind
screen
studi
drug
although
proven
use
treatment
sever
patholog
signific
downsid
like
import
side
effect
low
effici
discov
design
new
drug
gener
overcom
difficulti
process
discoveri
develop
novel
drug
known
timeconsum
expens
averag
standard
process
discoveri
develop
drug
market
take
year
furthermor
averag
cost
research
develop
effect
drug
estim
billion
usd
context
surpris
develop
new
strategi
last
decad
emerg
make
process
much
ration
effici
use
new
supercomput
combin
knowledg
experi
research
day
physician
biologist
chemist
physicist
comput
scientist
work
hand
hand
goal
offer
patient
better
select
drug
improv
qualiti
life
nevertheless
still
long
way
go
field
drug
discoveri
say
drug
design
articl
first
introduc
concept
computeraid
drug
discoveri
design
summari
lead
comput
techniqu
includ
drugreposit
approach
lead
optim
techniqu
second
section
describ
approach
success
appli
addit
review
concept
ration
design
present
repres
exampl
molecul
identifi
mean
key
principl
illustr
case
studi
explor
field
anticanc
drug
design
demonstr
research
advanc
aid
silico
drug
design
potenti
creat
novel
anticanc
drug
sinc
advent
xray
diffract
unveil
chemic
composit
threedimension
geometri
small
organ
molecul
larg
number
protein
solv
either
xray
nuclear
magnet
reson
nmr
spectroscopi
avail
open
access
protein
databas
http
wwwrcsborg
inform
allow
research
understand
character
mani
physiolog
process
base
interact
protein
protein
small
molecul
ligand
case
drugtarget
bind
max
perutz
john
kendrew
award
nobel
prize
chemistri
first
solv
highresolut
structur
protein
myoglobin
sinc
sever
studi
crystallographi
determin
protein
structur
award
nobel
prize
recent
nobel
prize
chemistri
award
jointli
brian
kobilka
robert
lefkowitz
structur
function
studi
gproteincoupl
receptor
gpcr
chemic
composit
rel
posit
atom
target
quest
find
hit
molecul
could
potenti
act
drug
evolv
consider
blind
screen
process
hope
find
molecular
hit
essenti
serendip
approach
often
call
ration
drug
discoveri
design
case
first
angiotensinconvert
enzym
ace
inhibitor
capoten
captopril
first
drug
optim
use
structur
inform
nelfinavir
mesyl
viracept
hiv
proteas
inhibitor
first
drug
design
complet
driven
structur
target
approv
us
market
discoveri
begin
frantic
career
search
novel
faster
cheaper
methodolog
comput
algorithm
techniqu
develop
design
new
drug
moreov
sampl
compound
target
screen
process
less
time
acquir
priori
key
knowledg
expertis
design
librari
chemic
compound
screen
precis
manner
solv
protein
structur
high
resolut
relev
revolut
came
comput
model
base
simpl
physic
law
abl
mimic
interact
organ
molecul
atom
atom
apart
structur
molecul
electrostat
charg
dipol
atom
van
der
waal
radii
paramet
coval
bond
torsion
dihedr
angl
consid
research
today
approach
real
system
use
virtual
silico
experi
support
comput
facil
power
workstat
supercomput
advanc
keyston
pave
way
ration
approach
queri
effici
select
fewer
side
effect
drug
time
make
process
cheaper
less
timeconsum
present
technolog
screen
compound
less
time
lower
cost
possibl
virtual
screen
computeraid
drug
discoveri
design
caddd
era
comput
simul
chemic
system
trigger
possibl
field
allow
research
make
silico
improv
among
advanc
resolut
structur
use
comput
model
optim
design
new
compound
understand
character
atom
mechan
previou
drug
natur
substanc
furthermor
break
paradigm
orthoster
drug
drug
bind
target
specif
activ
site
expand
search
therapeut
molecul
alloster
modul
bitop
drug
impact
methodolog
well
scienc
develop
understand
model
allatom
chemic
biochem
process
reaction
comput
physic
perspect
recent
recogn
nobel
prize
chemistri
physicist
martin
karplu
michael
levitt
togeth
chemist
arieh
warshel
current
mani
technolog
develop
boost
effici
drug
discoveri
process
sinc
emerg
caddd
experienc
rapid
increas
develop
mani
differ
research
group
around
world
made
signific
contribut
also
emerg
har
variou
sourc
inform
facilit
develop
new
drug
modul
behavior
therapeut
interest
protein
target
acceler
earlystag
pharmaceut
research
rapid
develop
caddd
technolog
provid
environ
expedit
drug
discoveri
process
enabl
huge
librari
compound
screen
synthes
short
time
low
cost
today
caddd
wide
use
term
repres
comput
tool
sourc
storag
manag
analysi
model
compound
use
almost
everi
stage
drugdiscoveri
project
lead
discoveri
optim
target
identif
valid
even
preclin
trial
evid
comput
drug
design
success
field
drug
develop
reflect
signific
number
new
drug
entiti
current
clinic
evalu
comput
drug
design
emerg
har
differ
sourc
inform
facilit
develop
new
drug
modul
behavior
therapeut
interest
protein
target
comput
approach
classifi
mainli
two
famili
ligandand
structurebas
method
ligandbas
method
use
exist
knowledg
activ
compound
target
predict
new
chemic
entiti
present
similar
behavior
given
singl
known
activ
molecul
librari
molecul
may
use
deriv
pharmacophor
model
defin
minimum
necessari
structur
characterist
molecul
must
possess
order
bind
target
interest
comparison
activ
molecul
librari
often
perform
via
fingerprintbas
similar
search
molecul
repres
bit
string
indic
presenceabs
predefin
structur
descriptor
contrast
structurebas
method
reli
target
structur
inform
determin
whether
new
compound
like
bind
interact
receptor
one
advantag
structurebas
drug
design
method
prior
knowledg
activ
ligand
requir
drug
structur
possibl
design
new
ligand
elicit
therapeut
effect
therefor
structurebas
approach
contribut
develop
new
drug
discoveri
optim
initi
lead
compound
current
combin
ligandand
structurebas
method
becom
common
approach
virtual
screen
sinc
hypothes
integr
enhanc
strength
reduc
drawback
method
section
repres
comput
approach
use
design
optim
develop
new
drug
describ
although
remark
differ
among
share
common
goal
harvest
potenti
ligand
hit
capabl
bind
target
extens
databas
gener
small
chemic
compound
figur
achiev
goal
mani
essenti
data
prepar
structur
gener
conform
analysi
figur
workflow
hit
identif
data
prepar
find
new
lead
standard
silico
drug
design
cycl
consist
dock
score
rank
initi
hit
base
steric
electrostat
interact
target
site
commonli
refer
virtual
screen
gener
absenc
structur
inform
receptor
one
bioactiv
compound
avail
ligandbas
virtual
prescreen
util
prescreen
method
carri
similar
search
basic
principl
behind
similar
search
screen
databas
similar
compound
backbon
lead
molecul
b
mani
situat
similar
search
databas
perform
use
chemic
inform
first
gener
hit
c
one
altern
approach
employ
ligandbas
pharmacophor
strategi
often
partner
structurebas
dock
use
stringent
score
matrix
determin
rel
score
made
match
two
charact
sequenc
align
enhanc
enrich
initi
hit
identifi
best
compound
comput
evalu
second
gener
hit
second
phase
molecular
interact
target
hit
often
identifi
ligandbas
site
optim
metric
uniqu
molecular
chemotyp
e
comput
algorithm
compound
fragment
compound
databas
posit
select
region
structur
dock
compound
score
rank
base
steric
electrostat
interact
target
site
f
structur
determin
target
complex
promis
lead
first
cycl
reveal
site
compound
optim
increas
potenc
step
decis
made
order
elimin
irrelev
compound
begin
end
show
better
potenti
activ
side
effect
show
interact
drug
process
perform
assist
comput
algorithm
call
virtual
screen
late
pharmacophor
approach
becom
quit
import
tool
drug
discoveri
due
absenc
structur
potenti
target
method
pharmacophor
model
quantit
structureact
relationship
qsar
give
use
insight
natur
targetligand
interact
consequ
result
predict
model
suitabl
lead
discoveri
optim
ligandbas
design
approach
reli
knowledg
structur
activ
ligand
interact
target
interest
predict
new
chemic
entiti
similar
behavior
argument
justifi
success
new
drug
design
base
featur
preexist
ligand
concept
known
molecular
similar
compound
high
structur
similar
like
similar
activ
profil
methodolog
consid
indirect
approach
drug
discoveri
usual
use
structur
target
unknown
predict
sever
way
use
known
activ
molecul
set
key
pattern
screen
small
molecul
librari
first
simplest
approach
use
molecular
descriptor
featur
physicochem
properti
molecular
weight
volum
geometri
surfac
area
atom
type
dipol
moment
polariz
molar
refract
octanolwat
partit
coeffici
log
p
planar
structur
electroneg
solvat
properti
obtain
experiment
measur
theoret
model
use
descriptor
compar
refer
molecul
set
molecul
larg
librari
compound
low
cost
task
done
effici
use
symbol
represent
molecul
descriptor
encod
bit
string
indic
presenc
absenc
predefin
properti
classifi
accord
differ
type
molecular
represent
constitut
descriptor
count
descriptor
list
structur
fragment
fingerprint
graph
invari
quantumchem
descriptor
surfac
volum
descriptor
anoth
ligandbas
approach
precis
molecular
descriptor
use
pharmacophor
model
ligand
ligandbas
pharmacophor
model
given
set
known
activ
compound
refer
next
step
use
molecular
descriptor
addit
structur
molecul
build
call
pharmacophor
model
accord
intern
union
pure
appli
chemistri
iupac
pharmacophor
defin
ensembl
steric
electron
featur
necessari
ensur
optim
supramolecular
interact
specif
biolog
target
trigger
block
biolog
respons
therefor
structur
overlap
space
featur
steric
interact
posit
neg
charg
group
hydrogen
bond
donor
acceptor
hydrophob
region
aromat
ring
pattern
molecul
repres
probabl
characterist
geometr
constraint
use
consensu
model
screen
small
molecul
librari
new
compound
show
high
degre
complementar
pharmacophor
like
activ
protein
target
interest
thu
requir
detail
fine
studi
approach
use
extens
de
novo
design
virtual
screen
lead
optim
multitarget
drug
design
becom
key
comput
strategi
facilit
drug
discoveri
absenc
macromolecular
target
structur
qsar
method
consist
find
simpl
equat
use
calcul
properti
molecular
structur
compound
qsar
model
predictor
includ
physicochem
properti
theoret
molecular
descriptor
chemic
result
simpl
mathemat
relationship
establish
applic
qsar
extend
molecular
design
purpos
includ
predict
differ
kind
biolog
activ
lead
compound
optim
predict
new
structur
lead
drug
discoveri
process
build
qsar
model
similar
apart
type
properti
predict
consist
sever
step
lead
design
new
compound
desir
activ
profil
first
step
involv
select
train
set
compound
experiment
activ
build
qsar
model
ideal
activ
cover
rang
possibl
valu
activ
next
step
comput
descriptor
contain
suffici
relev
inform
biolog
phenomenon
despit
initi
difficulti
predict
advanc
descriptor
variabl
valuabl
descriptor
calcul
one
includ
qsar
model
correl
coeffici
give
quantit
measur
well
descriptor
describ
activ
thu
descriptor
highest
correl
coeffici
pick
next
data
analysi
need
calcul
best
mathemat
express
link
togeth
descriptor
biolog
activ
inform
relat
essenti
featur
chemic
biolog
data
structur
obtain
final
step
valid
predict
nontest
compound
take
place
experiment
valid
model
need
done
exampl
verifi
alreadi
biolog
test
compound
testset
qsar
predict
within
accept
restrict
may
use
extens
predict
compound
result
interpret
propos
design
new
compound
desir
activ
outlin
contrast
ligandbas
method
structurebas
method
work
directli
structur
macromolecular
target
macromoleculeligand
complex
approach
reli
structur
target
inform
determin
whether
new
compound
like
bind
high
affin
region
interact
modifi
behavior
protein
follow
therapeut
effect
way
target
use
mold
interact
small
molecul
chemic
librari
comput
simul
subsequ
show
better
fit
bind
site
select
strategi
often
use
improv
effect
known
ligand
use
biochem
inform
ligandreceptor
interact
order
postul
ligand
refin
small
chemic
modif
inform
regard
bind
site
exist
steric
complementar
ligand
improv
increas
affin
receptor
inde
use
crystal
structur
complex
specif
region
ligand
fit
poorli
within
activ
site
target
chemic
modif
lower
energet
potenti
make
van
der
waal
interact
neg
may
postul
improv
complementar
receptor
similar
fashion
function
group
ligand
chang
order
augment
electrostat
complementar
receptor
structur
target
solv
high
resolut
xray
nmr
molecular
model
bind
site
precis
enough
best
possibl
start
point
structurebas
drug
design
applic
dock
algorithm
molecular
dock
molecular
simul
techniqu
wide
use
research
interact
ligand
target
dock
process
virtual
simul
energet
interact
ligand
target
includ
predict
best
ligand
conform
orient
within
bind
site
dock
method
predict
prefer
orient
one
small
molecul
bound
target
form
stabl
complex
consist
multipl
step
process
begin
applic
dock
algorithm
pose
small
molecul
within
activ
site
target
algorithm
complement
score
function
design
predict
biolog
activ
evalu
interact
compound
potenti
target
earli
score
function
evalu
compound
fit
base
calcul
approxim
shape
electrostat
complementar
preselect
conform
often
assess
use
complex
score
scheme
detail
treatment
electrostat
van
der
waal
interact
inclus
least
solvat
entrop
effect
thu
dock
program
mainli
three
purpos
first
dock
program
serv
identifi
potenti
ligand
librari
chemic
compound
second
predict
bind
mode
potenti
ligand
known
ligand
final
use
predict
bind
pose
program
calcul
put
bind
affin
use
score
identifi
compound
like
bind
drug
target
dock
program
shown
success
screen
larg
chemic
librari
reduc
manag
subset
enrich
binder
case
true
interact
predict
ligand
pose
often
correl
well
experiment
solv
proteinligand
complex
structurebas
method
led
identif
novel
drug
bind
pose
predict
consid
one
strength
sinc
molecular
dock
play
central
role
predict
proteinligand
interact
extens
use
drug
hit
discoveri
lead
optim
pharmacophor
definit
mention
still
valid
appli
inform
avail
design
drug
structur
target
protocol
structurebas
pharmacophor
model
involv
analysi
complementari
chemic
featur
activ
site
spatial
relationship
subsequ
pharmacophor
model
assembl
select
featur
case
pharmacophor
defin
analysi
target
bind
site
macromolecul
without
ligand
base
base
macromoleculeligandcomplex
macromoleculeligandcomplexbas
approach
conveni
ligand
locat
ligandbind
site
macromolecular
target
key
interact
point
ligand
macromolecul
need
determin
spatial
arrang
properti
hydrogen
bond
acceptor
donor
basic
acid
group
partial
charg
aromat
aliphat
hydrophob
region
activ
site
virtual
mold
defin
much
lower
comput
complex
target
describ
allatom
level
fact
bring
possibl
perform
virtual
screen
pharmacophor
search
larg
librari
compound
feasibl
reason
cost
time
structurebas
pharmacophor
model
extens
use
drug
hit
discoveri
appli
identif
novel
ligand
use
databas
search
approach
twentyseven
homolog
model
transport
predict
pharmacophor
model
drug
transport
gener
publish
date
yet
model
ie
pgp
dat
bcrp
recent
trend
toward
integr
structureand
ligandbas
method
use
inform
structur
protein
biolog
physicochem
properti
bound
ligand
respect
aim
enhanc
reliabl
computeraid
drug
design
approach
combin
relev
inform
ligand
protein
simplest
build
pharmacophor
find
potenti
ligand
perform
dock
studi
target
constitut
combin
approach
integr
approach
fall
two
class
interactionbas
dock
similaritybas
method
interactionbas
method
focu
identifi
key
interact
protein
ligand
use
avail
physicochem
data
interact
use
screen
small
molecul
librari
compound
capabl
produc
interact
profil
contrast
dock
similaritybas
method
merg
structurebas
dock
method
ligand
similar
method
combin
virtual
screen
becom
effici
allow
explor
librari
small
molecul
comput
resourc
techniqu
perform
comput
ration
drug
design
research
repeat
exasper
number
trialanderror
procedur
target
protein
laboratori
test
hundr
compound
avail
chemic
librari
mani
time
challeng
afford
big
pharmaceut
compani
institut
matter
luck
expertis
intuit
rest
laboratori
number
possibl
chemic
compound
exhaust
search
around
moreov
amount
small
molecul
test
filter
silico
virtual
screen
vs
use
power
comput
process
virtual
screen
consist
select
compound
larg
databas
use
comput
tool
rather
physic
screen
process
activ
compound
could
modul
particular
biomolecular
pathway
rapidli
identifi
relev
techniqu
costbenefit
ratio
justifi
presenc
approach
almost
drug
design
develop
project
even
though
number
differ
algorithm
strategi
success
virtual
screen
matter
constant
debat
depend
natur
project
virtual
screen
offer
mani
advantag
physic
screen
significantli
less
resourceintens
faster
addit
even
compound
yet
avail
first
evalu
virtual
screen
found
promis
bought
synthes
thu
million
compound
analyz
virtual
screen
howev
import
keep
mind
virtual
screen
still
rel
coars
filter
particularli
consid
structurebas
screen
predict
bind
affin
remain
one
holi
grail
comput
chemistri
nevertheless
sever
success
exampl
publish
recent
review
rapid
develop
caddd
technolog
methodolog
provid
environ
expedit
drug
discoveri
process
enabl
huge
librari
compound
screen
synthes
short
time
low
cost
last
year
numer
project
search
new
optim
drug
success
appli
approach
illustr
relev
applic
regard
silico
target
predict
hit
identif
lead
optim
review
spring
sever
acut
respiratori
syndrom
sar
outbreak
occur
china
chen
et
al
identifi
dockingbas
vs
old
drug
cinanserin
serotonin
antagonist
potenti
inhibitor
proteas
sar
import
sar
coronaviru
replicas
polyprotein
process
follow
experiment
test
show
cinanserin
could
inde
inhibit
proteas
nontox
drug
concentr
mm
potenti
kill
sar
viru
author
conclud
old
cheap
drug
establish
safeti
record
cinanserin
could
use
emerg
treatment
stockpil
futur
sar
pandem
fan
et
al
conduct
anoth
case
studi
silico
target
predict
author
establish
system
biolog
approach
combin
human
reassembl
signal
network
microarray
gene
express
data
studi
drugtarget
interact
provid
uniqu
insight
offtarget
advers
effect
torcetrapib
result
suggest
plateletderiv
growth
factor
receptor
pdgfr
hepatocyt
growth
factor
receptor
hgfr
epiderm
growth
factor
receptor
tyrosin
kinas
highli
relev
unfavor
effect
furthermor
obtain
potenti
offtarget
torcetrapib
identifi
employ
revers
dock
strategi
anoth
case
studi
includ
fibroblast
growth
factor
receptor
fgfr
consist
extracellular
ligand
domain
compos
singl
transmembran
helix
domain
three
immunoglobulinlik
domain
intracellular
domain
tyrosin
kinas
activ
target
treatment
variou
human
cancer
chen
et
al
use
revers
pharmacophor
map
approach
identifi
target
candid
activ
compound
previous
synthes
show
signific
vitro
antiprolif
effect
silico
target
predict
reveal
tyrosin
kinas
might
potenti
target
repres
compound
follow
structur
optim
structureact
relationship
sar
analysi
aid
molecular
dock
simul
atpbind
site
demonstr
acenaphtho
pyrrol
carboxyl
acid
ester
potent
inhibitor
valu
rang
nm
exhibit
favor
growth
inhibit
properti
fgfrexpress
cancer
cell
line
lead
compound
desir
activ
found
screen
process
activ
need
confirm
upon
retest
lead
discoveri
dock
process
involv
predict
ligand
conform
orient
within
target
bind
site
one
wide
employ
techniqu
usual
embed
workflow
differ
silico
approach
identif
small
molecul
process
transform
highcont
lead
seri
key
activ
modern
drug
discoveri
three
compound
repres
exampl
lead
discoveri
optim
zanamivir
dorzolamid
captopril
zanamivir
relenza
gilead
scienc
neuraminidas
inhibitor
use
treatment
prophylaxi
influenza
caus
influenza
b
virus
structur
influenza
neuraminidas
protein
determin
xray
crystallographi
topolog
activ
site
elucid
allow
first
time
design
inhibitor
prevent
viru
escap
host
cell
infect
other
achiev
accomplish
use
structurebas
drug
design
approach
variou
sialic
acid
analog
develop
aid
computerassist
model
activ
site
hand
dorzolamid
trusopt
merck
carbon
anhydras
inhibitor
antiglaucoma
agent
decreas
product
aqueou
humor
first
drug
human
therapi
result
structurebas
drug
design
ab
initio
calcul
achiev
design
dorzolamid
success
inclus
two
concept
project
crucial
prototyp
compound
gener
two
enantiom
activesit
caviti
amphiphil
final
design
antihypertens
drug
captopril
capoten
bristolmyerssquibb
angiotensinconvert
enzym
ace
inhibitor
use
treatment
type
congest
heart
failur
hypertens
exampl
earli
endeavor
success
structurebas
ligandbas
drug
design
inform
necessari
design
captopril
includ
knowledg
enzymat
mechan
ace
similar
carboxypeptidas
differ
ace
cleav
dipeptid
carboxypeptidas
cleav
singl
amino
acid
residu
carboxyl
end
protein
structureact
relationship
sar
studi
critic
guid
synthesi
captopril
nm
develop
new
anticanc
drug
prove
elabor
costli
timeconsum
process
caddd
becom
increasingli
import
given
advantag
much
less
invest
technolog
resourc
time
requir
due
dramat
increas
inform
avail
genom
small
molecul
protein
structur
comput
tool
integr
almost
everi
stage
drug
discoveri
develop
given
structur
target
molecul
chemic
compound
may
potenti
higher
affin
target
design
ration
aid
comput
method
recent
year
sever
case
success
applic
structurebas
drug
design
report
interest
exampl
structurebas
pharmacophor
model
identif
upregul
modul
apoptosi
puma
inhibitor
puma
proapoptot
protein
member
protein
famili
express
regul
tumor
suppressor
puma
ablat
inhibit
lead
apoptosi
defici
underli
increas
risk
cancer
develop
therapeut
resist
cancertreat
target
central
mitochondriamedi
cell
death
interact
known
antiapoptot
famili
member
base
bind
protein
protein
approach
use
identifi
small
molecul
modul
interact
therefor
inhibit
apoptosi
effort
focus
develop
famili
inhibitor
mimic
action
proapoptot
domain
compound
identifi
comput
model
structurebas
design
highthroughput
screen
natur
product
synthet
librari
hand
liu
et
al
report
combinatori
comput
strategi
discov
potenti
inhibitor
insulinlik
growth
receptor
associ
sever
cancer
includ
breast
prostat
lung
cancer
belong
tyrosin
kinas
famili
play
pivot
role
signal
pathway
involv
cell
growth
prolifer
apoptosi
initi
hit
obtain
hierarch
vs
subsequ
use
queri
scaffold
substructur
search
build
focus
librari
librari
screen
inhous
pharmacophoreconstrain
dock
protocol
eventu
compound
exhibit
inhibitori
activ
enzymat
assess
strikingli
two
potent
inhibitor
demonstr
excel
inhibitori
potenc
nm
respect
also
present
signific
select
insulin
receptor
ir
highli
homolog
author
conclud
promis
select
inhibitor
asid
potenti
antitumor
agent
could
investig
molecular
probe
differenti
biolog
function
ir
anoth
success
exampl
small
molecul
design
use
ligandbas
approach
case
tubulin
inhibitor
tubulin
polymer
essenti
compon
cell
cycl
progress
cell
divis
repres
import
target
anticanc
therapi
sever
antimitot
agent
paclitaxel
colchicin
vinca
alkaloid
discov
clinic
use
often
show
signific
toxic
low
bioavail
rapidli
acquir
resist
result
overexpress
drugresist
pump
eject
antimitot
inhibitor
cell
howev
due
unfavor
properti
research
devot
substanti
effort
discov
new
agent
toler
effici
properti
particularli
believ
antimitot
agent
could
work
diminish
blood
suppli
cancer
tumor
liou
et
al
base
model
gener
set
indolederiv
synthes
origin
potenti
tubulin
inhibit
use
structureact
relationship
sar
analysi
drive
compound
chosen
inhibitori
valu
span
three
order
magnitud
nm
base
chemic
similar
compound
author
select
four
common
pharmacophor
featur
includ
hydrogen
bond
donor
hydrogen
bond
acceptor
hydrophob
group
hydrophob
aromat
group
construct
chemic
librari
subsequ
compound
biolog
test
use
human
oral
squamou
carcinoma
cell
line
kb
among
biolog
test
compound
four
found
inhibit
kb
cell
line
valu
nm
respect
potent
compound
four
activ
molecul
also
found
inhibit
prolifer
cancer
cell
line
like
breast
cancer
human
nonsmallcel
lung
cancer
human
central
nervou
system
cancer
valu
nm
nm
nm
respect
anoth
exampl
small
molecul
design
use
comput
approach
case
ikappab
kinas
inhibitor
key
player
nfb
signal
pathway
repres
yet
anoth
potenti
target
treatment
cancer
addit
inflamm
noha
et
al
decid
use
ligandbas
pharmacophor
model
identifi
new
compound
affin
ligandbas
pharmacophor
model
studi
base
set
five
compound
high
activ
valu
nm
less
least
severalfold
differ
select
nfb
attempt
develop
inhibitorspecif
pharmacophor
model
model
refin
use
dataset
extract
literatur
biolog
inact
compound
activ
compound
sever
random
decoy
compound
top
ten
highscor
compound
test
vitro
among
potent
inhibitor
compound
could
inhibit
valu
approxim
cellbas
analys
also
conduct
test
abil
compound
inhibit
nfb
activ
cell
stabli
transfect
carri
luciferas
report
gene
activ
promot
compos
multipl
copi
nfb
respons
element
compound
found
cellbas
assay
valu
approxim
exhibit
dosedepend
activ
inhibit
luciferas
activ
therefor
noha
et
al
abl
demonstr
success
applic
ligandbas
approach
identif
low
micromolar
inhibitor
attempt
articul
iter
process
structurebas
design
lead
develop
drug
pharmacolog
potenti
exampl
literatur
list
tabl
evolut
significantli
sophist
molecular
model
tool
use
highthroughput
xray
crystallographi
target
alon
complex
small
molecul
ration
drug
design
techniqu
becom
indispens
instrument
develop
targetbas
therapi
consid
relev
exampl
cite
import
approach
research
group
interest
find
molecul
capabl
inhibit
transcript
factor
call
yinyang
factor
observ
overexpress
cancer
patient
activ
significantli
involv
chemotherapi
resist
mechan
pediatr
patient
acut
lymphoblast
leukemia
report
overexpress
vitro
inhibit
cell
line
show
import
implic
chemoresist
cell
base
find
research
group
particularli
interest
identifi
inhibitor
activ
transcript
factor
employ
caddd
tool
elucid
structur
sitebind
domain
provid
new
framework
understand
function
transcript
factor
lead
develop
ration
drug
design
treatment
overview
structur
activ
action
lymphoblast
leukemia
chemoresist
structur
inform
highthroughput
screen
use
drug
discoveri
provid
futur
process
novel
drug
discoveri
develop
recogn
expens
timeconsum
howev
thank
recent
advanc
develop
physic
chemic
model
simul
biomolecular
process
togeth
product
increasingli
power
comput
resourc
discov
design
new
drug
anticanc
drug
afford
task
mani
research
institut
laboratori
today
requir
comput
hardwar
softwar
expertis
biochemistri
biophys
biolog
mani
project
previous
demand
signific
invest
time
money
done
today
small
group
research
workstat
moreov
challeng
project
even
conceiv
two
decad
ago
today
tackl
access
supercomput
use
caddd
approach
research
acceler
step
project
implement
molecular
simul
biomolecular
research
project
increas
knowledg
field
structur
chemic
biolog
point
tool
consid
use
facil
laboratori
optim
techniqu
method
occur
way
natur
theoret
feedback
signal
system
comput
model
gener
use
predict
check
experiment
result
biologist
physician
demand
approach
accur
comput
scientist
